Search CatalystAlert
Search for companies, drugs, and catalysts
Search CatalystAlert
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
No catalyst events have been recorded for this drug yet.
4 competitors in Sickle Cell Disease
View Full LandscapeNo patent data available. Pre-approval drugs may not have Orange Book listings.
Oxbryta
Oxbryta is indicated for the treatment of haemolytic anaemia due to sickle cell disease (SCD) in adults and paediatric patients 12 years of age and older as monotherapy or in combination with hydroxycarbamide.
Vaccines, Pneumococcal
Diabetes Mellitus
Renal Transplantation
Major Depressive Disorder
Complicated Intra-abdominal Infections